Teva Pharmaceutical Industries (NYSE:TEVA) EVP Eliyahu Sharon Kalif Sells 106,563 Shares of Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Eliyahu Sharon Kalif sold 106,563 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the completion of the transaction, the executive vice president owned 65,621 shares in the company, valued at $2,237,676.10. This represents a 61.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Eliyahu Sharon Kalif also recently made the following trade(s):

• On Thursday, May 14th, Eliyahu Sharon Kalif sold 153,251 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $35.61, for a total value of $5,457,268.11.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $32.88 on Wednesday. The company has a market capitalization of $37.80 billion, a price-to-earnings ratio of 24.72, a P/E/G ratio of 3.44 and a beta of 0.84. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The business’s 50-day moving average is $33.40 and its 200-day moving average is $32.12.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The company had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Aster Capital Management DIFC Ltd acquired a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $25,000. Cornerstone Planning Group LLC grew its holdings in Teva Pharmaceutical Industries by 547.1% during the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after purchasing an additional 755 shares during the last quarter. Allworth Financial LP grew its holdings in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares during the last quarter. Grove Bank & Trust grew its holdings in Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Truist Financial increased their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Piper Sandler restated an “overweight” rating and issued a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Barclays increased their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, Bank of America increased their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $41.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.